FDA Approves Cyltezo as Interchangeable Biosimilar With Humira

Boehringer Ingelheim said the FDA approved the supplemental biologics license application for Cyltezo as the first Interchangeable biosimilar with Humira.

• The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases and this latest approval designates it as Interchangeable across all of these indications

To view the source of this information, click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used with permission.